A Study of MEDI-575 in Patients With Advanced Solid Malignancies

• Status: Completed
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and tolerability of MEDI-575 in Japanese patients with advanced solid tumors (dose escalation part) and hepatocellular carcinoma (expansion part).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Collaborator: MedImmune LLC

Criteria

Inclusion Criteria:

• Having advanced solid malignancy for which no curative or standard therapies exist

• Karnofsky performance status of ≥60

• Patients must have histological confirmed diagnosis of HCC with no standard therapy available (for only expansion part)

Exclusion Criteria:

• Inadequate bone marrow reserve or organ function

• Major surgery within 4 weeks or minor surgery within 2 weeks prior to receipt of MEDI-575. Patients must have no unhealed wounds or unhealed fractures

• History of allergy or reaction to any component of the MEDI-575 and/or monoclonal antibody